曲妥珠单抗联合蒽环类药物应用于Her-2阳性乳腺癌的新辅助治疗初步临床研究

目的分析曲妥珠单抗同时联合蒽环、紫杉类药物应用于Her-2阳性乳腺癌新辅助治疗的疗效。方法 30例Her-2阳性可手术的乳腺癌患者,给予4周期ATH序贯2~4周期TH新辅助治疗,治疗后行乳腺癌改良根治术或保乳术,结果进行统计分析。结果 30例入组患者,完全缓解(Complete remission,CR)和部分缓解(Partial remission,PR)的患者共25例(80.0%),其中CR的7例(23.3%),无疾病进展(Progression disease,PD)病例;病理完全缓解(Pathological complete response,pCR)15例(50.0%)。结论 对于Her-2阳性的乳腺癌患者给予含蒽环、紫杉类及曲妥珠单抗的新辅助治疗,可以达到较高的临床获益率和病理学完全缓解率,不良反应可以耐受。

A preliminary clinical study on the neoadjuvant therapy of treating Her-2 positive breast cancer by applying trastuzumab together with anthracyclines

Objective To study a retrospective analysis of the clinical effect of the neoadjuvant therapy of treating Her-2 positive breast cancer by applying Trastuzumab together with athracyclines and taxane-based chemotherapy.Methods 30 patients with Her-2 positive operable breast cancer were accepted 4 cycles ATH which were followed by 2~4 cycles TH regimen neoadjuvant chemotherapy before modified radical　mastectomy or conserving surgery.Then a statistical analysis was made.Results Among the 30 concerned patients,25(80%)reached completly remissio and Partial remission,and 15(50%)obtained pathological complete remission.Conclusion A complete pathological remission as well as a considerably high clinical benefit ratio can be achieved by treating Her-2 positive breast cancer with Trastuzumab together with athracyclines and taxane-based chemotherapy.Adverse reaction is tolerable.